These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 25204404)
1. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Stuyckens K; Saad F; Xu XS; Ryan CJ; Smith MR; Griffin TW; Yu MK; Vermeulen A; Nandy P; Poggesi I Clin Pharmacokinet; 2014 Dec; 53(12):1149-60. PubMed ID: 25204404 [TBL] [Abstract][Full Text] [Related]
2. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231 [TBL] [Abstract][Full Text] [Related]
3. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060 [TBL] [Abstract][Full Text] [Related]
4. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309 [TBL] [Abstract][Full Text] [Related]
5. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
7. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037 [TBL] [Abstract][Full Text] [Related]
8. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968 [TBL] [Abstract][Full Text] [Related]
9. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Fizazi K; Flaig TW; Stöckle M; Scher HI; de Bono JS; Rathkopf DE; Ryan CJ; Kheoh T; Li J; Todd MB; Griffin TW; Molina A; Ohlmann CH Ann Oncol; 2016 Apr; 27(4):699-705. PubMed ID: 26609008 [TBL] [Abstract][Full Text] [Related]
10. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
11. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059 [TBL] [Abstract][Full Text] [Related]
12. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139 [TBL] [Abstract][Full Text] [Related]
13. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004 [TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE; Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341 [TBL] [Abstract][Full Text] [Related]
15. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637 [TBL] [Abstract][Full Text] [Related]
16. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; De Porre P; Vermeulen A; Poggesi I; Nandy P Clin Pharmacokinet; 2017 Jan; 56(1):55-63. PubMed ID: 27324190 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038 [TBL] [Abstract][Full Text] [Related]
18. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615 [TBL] [Abstract][Full Text] [Related]
19. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280 [TBL] [Abstract][Full Text] [Related]
20. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Roy S; Sun Y; Morgan SC; Wallis CJD; King K; Zhou YM; D'souza LA; Azem O; Cueto-Marquez AE; Camden NB; Spratt DE; Kishan AU; Saad F; Malone S Eur Urol; 2023 Jun; 83(6):571-579. PubMed ID: 36894488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]